Prostate-specific antigen failure risk factors in nonmetastatic unfavorable-risk prostate cancer
Research led by the Dana Farber Cancer Institute, Massachusetts, performed a secondary analysis of the Dana-Farber Cancer Institute 05-043 trial. In the paper, "Risk of Short-Term Prostate-Specific Antigen Recurrence and ...